$798 Million is the total value of Sarissa Capital Management LP's 12 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 7.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDCO | MEDICINES CO. | $210,100,000 | +37.1% | 4,202,000 | 0.0% | 26.33% | +37.8% | |
| AGN | ALLERGAN PLC | $175,442,000 | +0.5% | 1,042,500 | 0.0% | 21.99% | +1.1% | |
| BIIB | BIOGEN INC. | $149,703,000 | -0.4% | 643,000 | 0.0% | 18.76% | +0.1% | |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC. | $86,734,000 | -18.4% | 10,103,000 | +4.0% | 10.87% | -18.0% |
| INVA | INNOVIVA INC. | $65,790,000 | -27.6% | 6,242,000 | 0.0% | 8.24% | -27.2% | |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS INC. | $56,472,000 | -6.2% | 851,000 | +12.4% | 7.08% | -5.8% |
| JAZZ | Buy | JAZZ PHARMACEUTICALS PLC | $31,009,000 | +10.7% | 242,000 | +23.2% | 3.89% | +11.3% |
| PBYI | PUMA BIOTECHNOLOGY INC. | $15,254,000 | -15.3% | 1,417,000 | 0.0% | 1.91% | -14.8% | |
| MRSN | MERSANA THERAPEUTICS INC. | $5,925,000 | -61.0% | 3,750,000 | 0.0% | 0.74% | -60.8% | |
| RGLS | REGULUS THERAPEUTICS INC | $1,333,000 | -42.4% | 1,851,851 | 0.0% | 0.17% | -42.0% | |
| MRTX | MIRATI THERAPEUTICS INC. | $77,000 | -25.2% | 1,000 | 0.0% | 0.01% | -23.1% | |
| ABBV | ABBVIE INC. | $75,000 | +4.2% | 1,000 | 0.0% | 0.01% | 0.0% | |
| CYCN | Exit | CYCLERION THERAPEUTICS INC. | $0 | – | -250,000 | -100.0% | -0.36% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.